News
KRTX
329.83
0.00%
0.00
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies. The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. Long-term data of the drug reinforced findings of previous studies.
Reuters · 04/06 17:15
3 Potential Biotech Buyout Targets In 2024
Biotech sector saw a surge of M&A activity at the end of 2023. The small biotech sector surged by 50% off its late October lows. 2024 should be a solid year for acquisitions in the biotech/biopharma space. Big drug makers have large cash balances and face key patent expirations. Three potential buyout targets in 2024 are highlighted below.
Seeking Alpha · 03/19 14:16
Strike While The Market Is Hot
Companies are taking advantage of strong investor demand in the investment grade credit market. In the first two months of 2024, nearly 200 companies issue roughly $380 billion of new bonds in the U.S. Investment grade primary market. Monthly issuance totals for both January and February blew away the prior three-year averages of $138 billion.
Seeking Alpha · 03/19 05:45
Karuna Therapeutics: Statement of changes in beneficial ownership of securities
Press release · 03/18 22:38
*News On Karuna Therapeutics Inc. (KRTX) Now Under BMY
Dow Jones · 03/18 21:08
Karuna Therapeutics Undergoes Extensive Corporate Transformation
TipRanks · 03/18 13:23
*Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics
Dow Jones · 03/18 12:44
Weekly Report: what happened at KRTX last week (0311-0315)?
Weekly Report · 03/18 11:43
Validea Detailed Fundamental Analysis - KRTX
NASDAQ · 03/15 16:04
BUZZ-Moody's says pharma outlook turns 'positive' on GLP-1 drug push
Moody's says outlook for U.S. Pharmaceutical credit to "positive" from "stable" on GLP-1 and other blockbuster drugs push. Positive outlook reflects expectations of 4%-6% annual core earnings growth over the 12-18 months. Industry growth will benefit from rising use of blockbuster drugs.
Reuters · 03/14 14:35
Karuna Therapeutics Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 03/14 13:41
HC Wainwright & Co. Maintains Neutral on Karuna Therapeutics, Maintains $330 Price Target
Benzinga · 03/14 13:31
Analysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)
Karuna Therapeutics (KRTX) and Cannabist Company Holdings (CBSTF) both have neutral ratings from analysts. The analysts are neither bullish nor bearish on the stocks. The analyst consensus on KarunaTherapeutics is a Hold with an average price target of $330.00.
TipRanks · 03/14 12:30
Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires
Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires on Wednesday. Bristol- myers agreed to acquire neuroscience drug firm Karuna for $14 billion in December. Karuna's stock rose 2.4% in premarket trading.
Seeking Alpha · 03/14 11:44
Karuna Therapeutics: Current report
Press release · 03/12 22:20
Intra-Cellular Therapies Is On Fire
Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand its use to treat Major Depressive Disorder. In 2023, there were 36,000 psychiatrists prescribing the drug to schizophrenia and bipolar depression patients in the US.
Seeking Alpha · 03/11 23:11
Weekly Report: what happened at KRTX last week (0304-0308)?
Weekly Report · 03/11 11:39
HC Wainwright & Co. Reiterates Neutral on Karuna Therapeutics, Maintains $330 Price Target
Benzinga · 03/11 11:25
Analysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)
TipRanks · 03/11 10:30
More
Webull provides a variety of real-time KRTX stock news. You can receive the latest news about Karuna Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About KRTX
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline is primarily built on the therapeutic potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS), and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. The Company is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease (AD). The Company is also engaged in developing its investigational TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and plan to provide details regarding the expected development of KAR-2618.